Myasthenia	myasthenia	O	DISEASE	OTHERS	I
gravis	gravis	O	DISEASE	OTHERS	I
presenting	presenting	O	O	O	O
as	as	O	O	O	O
weakness	weakness	O	DISEASE	OTHERS	I
after	after	O	O	O	O
magnesium	magnesium	CHEMICALS	O	OTHERS	I
administration	administration	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
studied	studied	O	O	O	O
a	a	O	O	O	O
patient	patient	O	O	O	O
with	with	O	O	O	O
no	no	O	O	O	O
prior	prior	O	O	O	O
history	history	O	O	O	O
of	of	O	O	O	O
neuromuscular	neuromuscular	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
who	who	O	O	O	O
became	became	O	O	O	O
virtually	virtually	O	O	O	O
quadriplegic	quadriplegic	O	O	OTHERS	I
after	after	O	O	O	O
parenteral	parenteral	O	O	O	O
magnesium	magnesium	CHEMICALS	O	OTHERS	I
administration	administration	O	O	O	O
for	for	O	O	O	O
preeclampsia	preeclampsia	O	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
serum	serum	O	O	O	O
magnesium	magnesium	CHEMICALS	O	OTHERS	I
concentration	concentration	O	O	O	O
was	was	O	O	O	O
3.0	3.0	O	O	O	O
mEq/L	meq/l	O	O	O	O
,	,	O	O	O	O
which	which	O	O	O	O
is	is	O	O	O	O
usually	usually	O	O	O	O
well	well	O	O	O	O
tolerated	tolerated	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
magnesium	magnesium	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
stopped	stopped	O	O	O	O
and	and	O	O	O	O
she	she	O	O	O	O
recovered	recovered	O	O	O	O
over	over	O	O	O	O
a	a	O	O	O	O
few	few	O	O	O	O
days	days	O	O	O	O
.	.	O	O	O	O

While	while	O	O	O	O
she	she	O	O	O	O
was	was	O	O	O	O
weak	weak	O	O	O	O
,	,	O	O	O	O
2-Hz	2-hz	O	O	O	O
repetitive	repetitive	O	O	O	O
stimulation	stimulation	O	O	O	O
revealed	revealed	O	O	O	O
a	a	O	O	O	O
decrement	decrement	O	O	O	O
without	without	O	O	O	O
significant	significant	O	O	O	O
facilitation	facilitation	O	O	O	O
at	at	O	O	O	O
rapid	rapid	O	O	O	O
rates	rates	O	O	O	O
or	or	O	O	O	O
after	after	O	O	O	O
exercise	exercise	O	O	O	O
,	,	O	O	O	O
suggesting	suggesting	O	O	O	O
postsynaptic	postsynaptic	O	O	OTHERS	I
neuromuscular	neuromuscular	O	O	OTHERS	I
blockade	blockade	O	O	OTHERS	I
.	.	O	O	O	O

After	after	O	O	O	O
her	her	O	O	O	O
strength	strength	O	O	O	O
returned	returned	O	O	O	O
,	,	O	O	O	O
repetitive	repetitive	O	O	O	O
stimulation	stimulation	O	O	O	O
was	was	O	O	O	O
normal	normal	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
single	single	O	O	O	O
fiber	fiber	O	O	O	O
EMG	emg	O	O	O	O
revealed	revealed	O	O	O	O
increased	increased	O	O	O	O
jitter	jitter	O	O	O	O
and	and	O	O	O	O
blocking	blocking	O	O	O	O
.	.	O	O	O	O

Her	her	O	O	O	O
acetylcholine	acetylcholine	CHEMICALS	O	OTHERS	I
receptor	receptor	O	O	O	O
antibody	antibody	O	O	O	O
level	level	O	O	O	O
was	was	O	O	O	O
markedly	markedly	O	O	O	O
elevated	elevated	O	O	O	O
.	.	O	O	O	O

Although	although	O	O	O	O
paralysis	paralysis	O	DISEASE	OTHERS	I
after	after	O	O	O	O
magnesium	magnesium	CHEMICALS	O	OTHERS	I
administration	administration	O	O	O	O
has	has	O	O	O	O
been	been	O	O	O	O
described	described	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
known	known	O	O	O	O
myasthenia	myasthenia	O	DISEASE	OTHERS	I
gravis	gravis	O	DISEASE	OTHERS	I
,	,	O	O	O	O
it	it	O	O	O	O
has	has	O	O	O	O
not	not	O	O	O	O
previously	previously	O	O	O	O
been	been	O	O	O	O
reported	reported	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
the	the	O	O	O	O
initial	initial	O	O	O	O
or	or	O	O	O	O
only	only	O	O	O	O
manifestation	manifestation	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
disease	disease	O	O	O	O
.	.	O	O	O	O

Patients	patients	O	O	O	O
who	who	O	O	O	O
are	are	O	O	O	O
unusually	unusually	O	O	O	O
sensitive	sensitive	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
neuromuscular	neuromuscular	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
magnesium	magnesium	CHEMICALS	O	OTHERS	I
should	should	O	O	O	O
be	be	O	O	O	O
suspected	suspected	O	O	O	O
of	of	O	O	O	O
having	having	O	O	O	O
an	an	O	O	O	O
underlying	underlying	O	O	O	O
disorder	disorder	O	O	OTHERS	I
of	of	O	O	OTHERS	I
neuromuscular	neuromuscular	O	O	OTHERS	I
transmission	transmission	O	O	OTHERS	I
.	.	O	O	O	O

